Gara Jalqabaatti › Kansara Qara'a Non-Small Cell › Arizona › Tucson
Qorannoo klinikaalii Kansara Qara'a Non-Small Cell Tucson, AZ keessatti
Qorannoo 17 Kansara Qara'a Non-Small Cell f Tucson fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Namoota walitti qabaa jiraSadarkaa 3
- The University of Arizona Cancer Center - North Campus ( Site 0163), Tucson
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Exelixis Clinical Site #1, Tucson
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 3
- The University of Arizona Cancer Center - North Campus, Tucson
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Namoota walitti qabaa jiraSadarkaa 3
- Research Site, Tucson
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Namoota walitti qabaa jiraSadarkaa 3
- Southern Arizona VA Health Care System, Tucson
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Arizona Cancer Center at UMC North/University Medical Center, Tucson
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Namoota walitti qabaa jiraSadarkaa 3
- Research Site, Tucson
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Namoota walitti qabaa jiraSadarkaa 2/3
- Arizona Clinical Research Center, Tucson
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 3
- The University of Arizona Cancer Center - North Campus, Tucson
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Namoota walitti qabaa jiraSadarkaa 1/2
- USOR Arizona Oncology Associates, Tucson
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Namoota walitti qabaa jiraSadarkaa 1/2
- University of Arizona Cancer Center, Tucson
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- University of Arizona, Tucson
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Namoota walitti qabaa jiraSadarkaa 1
- University of Arizona Cancer Center - Tucson /ID# 262698, Tucson
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Namoota walitti qabaa jiraSadarkaa 2/3
- Banner University Medical Center - Tucson, Tucson
- University of Arizona Cancer Center-North Campus, Tucson
The Impact of Exercise on the Tumor Microenvironment in Patients With Lung Cancer
Namoota walitti qabaa jiraHojjettoota fayyaa simatamoo
- University of Arizona Cancer Center, Tucson
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Research Site 111, Tucson
Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases
Namoota walitti qabaa jiraSadarkaa 1
- The University of Arizona Cancer Center, Tucson
Qorannoo Kansara Qara'a Non-Small Cell magaalota biroo keessatti
- Houston, TXQorannoo 145
- New York City, NYQorannoo 121
- Arlington, VAQorannoo 104
- Nashville, TNQorannoo 97
- Boston, MAQorannoo 90
- Los Angeles, CAQorannoo 87
- St. Louis, MOQorannoo 73
- Chicago, ILQorannoo 61
- Baltimore, MDQorannoo 60
- San Antonio, TXQorannoo 59
- Columbus, OHQorannoo 57
- Washington, DCQorannoo 55
Qorannoo biroo Tucson keessatti
- Saree OljooQorannoo 20
- ObesityQorannoo 18
- Baayyee UlfaataaQorannoo 15
- Kansara MetastatikiiQorannoo 14
- Saree (Gosoota Hunda)Qorannoo 12
- Dhibee Onneessaa fi DhiigaQorannoo 12
- Kansarii ColorectalQorannoo 11
- Kansarii ProstateQorannoo 11
- Sukkaraa Gosa 2Qorannoo 11
- Dhukkubaa Harkaa SteatoticQorannoo 10
- Cufama OnneeQorannoo 10
- Dhiibbaa Dhiigaa Ol'aanaaQorannoo 10
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.